医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Data from Final Cohort of Patients in Patrys Multiple Myeloma Clinical Trial

2013年11月29日 PM03:10
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Patrys Limited (ASX:PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma (MM) will be presented at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA on 7- 10 December 2013.

To date eleven out of a total of twelve patients are currently available for response evaluation, including two out of three from the 4th and final treatment group. The 12th patient is not yet evaluable. This final group received four doses of PAT-SM6 at 6mg/kg/dose as per the protocol. To date, four out of eleven of the patients (36%) with end-stage, multi-resistant MM have shown evidence of stable disease according to the International Myeloma Working Group criteria.

The eleven patients (9 male and 2 female, median age 71 years) had, on average, received five prior lines of therapy including autologous stem cell transplantation and other novel marketed compounds including Velcade and Revlimid. Therapeutic options for such patients are usually limited to clinical trials and their median overall survival is around nine months.

All of the eleven evaluable patients tolerated PAT-SM6 very well. There were no drug-related serious adverse events and no dose-limiting toxicities.

These updated results will be presented by lead clinical investigator Dr. Leo Rasche from the Department of Haematology and Oncology, University Hospital of Würzburg. His presentation is titled “A monoclonal IgM antibody with specificity to heat shock protein GRP78/BIP shows anti-myeloma activity in vitro and in vivo, synergy in combination with Lenalidomide and safety in a pilot Phase I study”.

“Our trial with PAT-SM6 has produced some very exciting clinical data and it is particularly encouraging to see four patients, with end-stage multiple myeloma, respond so positively to treatment with this novel antibody,” commented Patrys’ CEO, Dr. Marie Roskrow. “These clinical data, in conjunction with an extensive preclinical package, have positioned our lead product, PAT-SM6, for the next clinical trial to be sponsored by Onyx Pharmaceuticals, a subsidiary of Amgen”.

CONTACT

Patrys Limited:
Dr. Marie
Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com
or
Patrys
IR
:
Rebecca Wilson
Buchan Consulting
P: 0417
382 391
rwilson@buchanwe.com.au
or
Patrys
Media:

Kellie Hanrick
Buchan Consulting
P: +61
3 9866 4722
khanrick@buchanwe.com.au

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024